Cargando…

Parkinson’s disease and diabetes mellitus: common mechanisms and treatment repurposing

In the last decade, attention has become greater to the relationship between neurodegeneration and abnormal insulin signaling in the central nervous system, as insulin in the brain is implicated in neuronal survival, plasticity, oxidative stress and neuroinflammation. Diabetes mellitus and Parkinson...

Descripción completa

Detalles Bibliográficos
Autores principales:	Labandeira, Carmen M., Fraga-Bau, Arturo, Arias Ron, David, Alvarez-Rodriguez, Elena, Vicente-Alba, Pablo, Lago-Garma, Javier, Rodriguez-Perez, Ana I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820685/ https://www.ncbi.nlm.nih.gov/pubmed/35017411 http://dx.doi.org/10.4103/1673-5374.332122

Ejemplares similares

Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson´s disease
por: Labandeira, Carmen M., et al.
Publicado: (2022)

NRF2 Activation and Downstream Effects: Focus on Parkinson’s Disease and Brain Angiotensin
por: Parga, Juan A., et al.
Publicado: (2021)

Restoring autophagic function: a case for type 2 diabetes mellitus drug repurposing in Parkinson’s disease
por: Greco, Marco, et al.
Publicado: (2023)

Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease
por: Garrido-Gil, Pablo, et al.
Publicado: (2012)

Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson’s Disease and Adverse Effects of L-DOPA
por: Muñoz, Ana, et al.
Publicado: (2020)

Drug repurposing strategies of relevance for Parkinson’s disease
por: Fletcher, Edward J. R., et al.
Publicado: (2021)

Repurposing bioenergetic modulators against protozoan parasites responsible for tropical diseases
por: Martínez-Flórez, Alba, et al.
Publicado: (2020)

Metformin Repurposing for Parkinson Disease Therapy: Opportunities and Challenges
por: Agostini, Francesco, et al.
Publicado: (2021)

Interactions between ibuprofen, ACE2, renin‐angiotensin system, and spike protein in the lung. Implications for COVID‐19
por: Valenzuela, Rita, et al.
Publicado: (2021)

Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19
por: Pedrosa, Maria A., et al.
Publicado: (2021)

Combined cell-based therapy strategies for the treatment of Parkinson’s disease: focus on mesenchymal stromal cells
por: Rodríguez-Pallares, Jannette, et al.
Publicado: (2022)

Crosstalk between insulin-like growth factor-1 and angiotensin-II in dopaminergic neurons and glial cells: role in neuroinflammation and aging
por: Rodriguez-Perez, Ana I., et al.
Publicado: (2016)

Insulin-Like Growth Factor-1 and Neuroinflammation
por: Labandeira-Garcia, Jose L., et al.
Publicado: (2017)

Drugs Modulating Renin-Angiotensin System in COVID-19 Treatment
por: Labandeira-Garcia, Jose L., et al.
Publicado: (2022)

Repurposing the yellow fever vaccine for intratumoral immunotherapy
por: Aznar, Maria Angela, et al.
Publicado: (2019)

The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets
por: Lago, Santiago G., et al.
Publicado: (2022)

Sustained Stable Disease with Capecitabine plus Bevacizumab in Metastatic Appendiceal Adenocarcinoma: A Case Report
por: Arias Ron, David, et al.
Publicado: (2020)

Dose‐dependent effect of mesenchymal stromal cells co‐grafted with dopaminergic neurons in a Parkinson's disease rat model
por: Rodriguez‐Pallares, Jannette, et al.
Publicado: (2021)

Repurposing Pimavanserin, an Anti-Parkinson Drug for Pancreatic Cancer Therapy
por: Ramachandran, Sharavan, et al.
Publicado: (2020)

Repurposing Simvastatin in Parkinson’s Disease Model: Protection Is throughout Modulation of the Neuro-Inflammatory Response in the Substantia nigra
por: Rubio-Osornio, Moisés, et al.
Publicado: (2023)

Angiotensin AT(1) and AT(2) receptor heteromer expression in the hemilesioned rat model of Parkinson’s disease that increases with levodopa-induced dyskinesia
por: Rivas-Santisteban, Rafael, et al.
Publicado: (2020)

Novel Interactions Involving the Mas Receptor Show Potential of the Renin–Angiotensin system in the Regulation of Microglia Activation: Altered Expression in Parkinsonism and Dyskinesia
por: Rivas-Santisteban, Rafael, et al.
Publicado: (2021)

Angiotensin System Autoantibodies Correlate With Routine Prognostic Indicators for COVID-19 Severity
por: Labandeira, Carmen M., et al.
Publicado: (2022)

Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience
por: Stott, Simon R. W., et al.
Publicado: (2021)

Rasch analysis of the living with chronic illness scale in Parkinson’s disease
por: Ambrosio, Leire, et al.
Publicado: (2020)

Reciprocal regulation between sirtuin-1 and angiotensin-II in the substantia nigra: implications for aging and neurodegeneration
por: Diaz-Ruiz, Carmen, et al.
Publicado: (2015)

Teaching the basics of repurposing mitochondria-targeted drugs: From Parkinson's disease to cancer and back to Parkinson's disease
por: Kalyanaraman, Balaraman
Publicado: (2020)

Drug Repurposing for Cancers With Limited Survival: Protocol for a Retrospective Cohort Study
por: Rodríguez-Molinero, Alejandro, et al.
Publicado: (2023)

The Cation/Calcium Channel of Sperm (CatSper): A Common Role Played Despite Inter-Species Variation?
por: Vicente-Carrillo, Alejandro, et al.
Publicado: (2023)

Drug repurposing: In-vitro anti-glycation properties of 18 common drugs
por: Rasheed, Saima, et al.
Publicado: (2018)

Drug Repurposing to Inhibit Histamine N-Methyl Transferase
por: Jiménez, Elvia Mera, et al.
Publicado: (2023)

Repurposing Platinum(IV) Prodrugs to Modulate Mitochondrial Metabolism
por: Zacharioudakis, Emmanouil, et al.
Publicado: (2023)

Nigral Neurons Degenerating in Parkinson's Disease Express the Angiotensin Receptor Type 1 Gene
por: Labandeira‐Garcia, Jose L., et al.
Publicado: (2022)

Brain renin-angiotensin system and dopaminergic cell vulnerability
por: Labandeira-García, Jose L., et al.
Publicado: (2014)

Validation study of the Parkinson’s Fatigue Scale in advanced Parkinson’s disease
por: Martinez-Martin, Pablo, et al.
Publicado: (2019)

Lipid Metabolism is the common pathologic mechanism between Type 2 Diabetes Mellitus and Parkinson's disease
por: Zhang, Xi, et al.
Publicado: (2020)

Integrating heterogeneous data to facilitate COVID-19 drug repurposing
por: Prieto Santamaría, Lucía, et al.
Publicado: (2022)

α-Synuclein inclusions in the skin of Parkinson's disease and parkinsonism
por: Rodríguez-Leyva, Ildefonso, et al.
Publicado: (2014)

Parkinson’s Disease Severity at 3 Years Can Be Predicted from Non-Motor Symptoms at Baseline
por: Ayala, Alba, et al.
Publicado: (2017)

Parkinson’s Disease Drug Development Since 1999: A Story of Repurposing and Relative Success
por: Boucherie, Deirdre M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v7ck1ti9uq5gbtirvrcggntacg